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The ‘silent epidemic’ of Alzheimer's disease is becoming a considerable social and economical problem in the developed countries. Especially
so, because we still cannot diagnose the disease early enough, and there is no disease-modifying treatment. At present the only available
therapeutic option is the use of cholinesterase inhibitors, which have mainly symptomatic short-term benefit for around one third of the patients
[1,2]. The solution to the problem would be the evidence-based design of early therapies, which could reverse/halt the cellular mechanisms that
precede the formation of the typical brain pathology. The development of new therapeutic strategies, however, is hindered by limited knowledge of
the pathogenic mechanisms that lead to the development of the sporadic form of the disease. Additionally, by the time the disease can be
diagnosed, using the currently available diagnostic protocols, the pathology has spread to large areas of the brain, causing irreversible damage and
functional disability [3]. It is imperative therefore that we find early biomarkers for sporadic Alzheimer's disease, which could identify patients
before substantial pathology develops.
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By definition biomarkers fall into two categories: biomarkers
of ‘exposure’ and biomarkers of ‘disease’.
The Biomarkers of exposure (antecedent biomarkers)
include measure of exposure to environmental risk factors and
genetic risk factors. They are particularly useful for risk
prediction. The biomarkers of ‘disease’ are indicators of
biological factors which represent either a prodromal manifes-
tation of the disease or a surrogate manifestation of the disease.
These markers allow the identification of individuals who are in
the pre-clinical stages of the disease and reduce heterogeneity in
clinical trials. If the marker also reflects the progression of the
disease it can be used as target for clinical trials [4].
1.1. The diagnosis of Alzheimer's disease
At present the diagnosis of ‘definite’Alzheimer's disease can
only be made by histopathological assessment after autopsy.
While the patient is alive the clinical diagnosis carries varying⁎ Tel.: +44 121 415 8135; fax: +44 121 414 4509.
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doi:10.1016/j.bbadis.2006.11.001amounts of uncertainty allowing the patients to fall into two
categories: probable or possible Alzheimer's disease (NINCDS-
ARDRA). Either category requires the patient to show clinical
signs of dementia. Additionally the clinical diagnosis relies
mainly on the exclusion of other neurological disorders, which
could cause dementia, rather than the identification of an
Alzheimer-specific clinical profile. While the positive predictive
value of clinical diagnosis of ‘probable AD’ is high (89–100%)
the diagnostic categories described above have a very high false
negative rate, excluding patients suffering from early/mid stages
of the disease [5].
1.2. Existing biomarkers for Alzheimer's disease
Because amyloid deposition in the brain is a defining feature
of AD the measurement of markers related to APP and β-
amyloid metabolism appeared attractive candidates as biomar-
kers for the disease. Despite much initial enthusiasm it
transpired that measurements of β-amyloid from plasma (or
serum) might relate to age or renal function but does not allow
the discrimination between healthy elderly controls and AD
patients (reviewed in [6]). Furthermore the plasma β-amyloid
levels do not correlate to dementia severity and did not reflect
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targeted to reduce β-amyloid accumulation in the brain
(reviewed in [6]). The possibility that the ratio of different
APP isoforms from platelets could be used for diagnosis and
monitoring disease progression and therapeutic effects was also
raised. However, technical limitations make this marker
difficult to standardise.
Cardiovascular risk factors, such as high cholesterol ApoE4
genotype hypertension and elevated plasma homocysteine
levels were also identified as risk factors for sporadic AD.
While they appear to be good antecedent biomarkers they do not
fulfil the role of biomarkers of ‘disease’. The same is true for
markers of oxidative stress (antioxidant levels and lipid
peroxidation products) (reviewed in [6]).
As the CSF is regarded as a mirror of the biochemical
changes occurring in the brain, considerable effort has been put
into identifying biomarkers for AD in the CSF. In turn total tau
and phospho-tau have been found to be elevated in AD patients
relative to controls while β-amyloid is reduced in the CSF of the
patient population. Although some studies claim good specifi-
city and sensitivity for these markers in differentiating AD
patients from controls, they do not differentiate AD from other
types of dementia (reviewed in [7]). The main shortcoming of
these markers is that they appear only once the disease has
caused considerable accumulation of AD-type pathology, and as
such they are relatively late markers.
A substantial number of imaging markers of the anatomy,
chemistry, physiology and pathology of AD became available in
recent years. Many of these have also been validated against
clinical and pathologic measured of the disease. Most of these
markers indicate a more rapid change over time in AD patients
than in age-matched controls. It also appears that some changes
identified by neuroimaging are more sensitive measures of
disease progression than the standard measures of cognitive
performance or behavioural assessments. As such, neuroima-
ging has the potential to provide more sensitive and reliable
markers of therapeutic efficacy, which could reduce the length of
clinical trials for disease modifying therapies (reviewed in [8]).
The main caveat of these techniques, however, is that imaging
reflects the accumulation of pathology (whether it is tissue
atrophy or the accumulation of AD-type pathology) and
subsequent functional deficit. Furthermore, due to large personal
variability, most of these imaging techniques allow patient
identification based only on the rate of change rather than on one
baseline observation. This makes the use of imaging techniques
for early diagnosis and trial stratification rather difficult.
In summary, so far there is no consistent, reproducible,
sensitive, or specific marker for AD diagnosis, risk, progres-
sion, or treatment effects. If we aspire to identify disease-
modifying therapies, which could delay the clinical symptoms
of AD in cognitively intact individuals who are at high risk, we
need markers, which reflect the pathophysiology of the disease.
2. Cell cycle and AD
The cell cycle hypothesis for the pathogenesis of Alzheimer's
disease was originally based on the observation that neurones inthe brain of elderly demented patients express cell division-related
proteins [9–11]. The differential expression of these cell cycle
markers suggested that the neurones in the adult nervous system
are able to re-enter the cell division cycle [12–14]. In normal
circumstances the cell cycle re-entry (from G0 to G1) is followed
by cell cycle arrest in an early stage (before the G1/S transition
point), when re-differentiation is still possible. It has also been
suggested that in the healthy brain the transient re-entry into the
cell cycle might be part of the synaptic remodelling process [15].
In Alzheimer's disease the G1/S control mechanisms fail.
Neurones are allowed to replicate their DNA [16] and progress
into the late, G2 phase of the cycle [9]. Since the neurones are
not able to divide, they remain in this very late stage of the cell
cycle. In turn the cellular mechanisms activated in the G2 phase
of the cycle drive the formation of neurofibrillary tangles and
amyloid plaques [17,18] in apoptosis incompetent neurones.
Based on this hypothesis the development of Alzheimer's
disease is a ‘two stage’ process: cell cycle re-entry followed by
regulatory failure at the G1/S transition point.
The hypothesis poses several questions. What are the
mitogenic stimuli that are able to drive mature differentiated
neurones into the cell division cycle? What are the con-
sequences of DNA replication in neurones that are 50–60 years
old? What are the causes of the cell cycle regulatory failure at
the G1/S transition point in some people but not others?
2.1. Mitogenic stimuli in the brain
The mitogenic stimulation of neurones is necessary to trigger
the cell cycle. Many of the identified risk factors for Alzheimer's
disease, such as elevated plasma homocysteine levels [19],
ageing [15], menopause [20,21], low thyroid levels [22,23], low
level prolonged oxidative stress [24,25], head injury or low
education, can either represent mitogenic signalling for neurones
or facilitate cell cycle re-entry in vulnerable neuronal populations
(reviewed by Arendt [15]). The link between synaptic plasticity
and cell cycle reactivation also explains how ApoE4 genotype,
which is associated with reduced plastic capacity of neurones
[26] is a risk factor for Alzheimer's disease.
2.2. The G1/S regulatory failure
While cell cycle re-entry of neurones appears to be a
prerequisite of Alzheimer's disease, on its own is not sufficient
to cause the disease [27,28]. As discussed above, the cell cycle
re-entry may just represent a short transient part of synaptic
remodelling in the healthy elderly [15]. The difference between
the healthy aging and AD seems to be the extent of cell cycle
progression rather than cell cycle re-entry. This suggests that the
transition from healthy ageing to AD is the point when neurones
bypass the G1/S restriction point and replicate their DNA.
The cell cycle is driven by the sequential expression and
activation of cyclin/cyclin dependent kinase (CDK) complexes and
inhibited by the cyclin dependent kinase inhibitors (CDKIs). At
each checkpoint different groups of cyclins kinases and CDKIs
ensure that the cell responds adequately to the extra- and intra-
cellular factors, which support either cell division or differentiation.
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events initiated by extracellular signals cell death is initiated.
At the G1/S transition point the cell cycle is driven by the
activity of the cyclin E/CDK2 complex and inhibited by the
members of the kip-cip protein family. There are three identified
proteins in this family of CDKIs.
The gene for the p21cip1 (p21waf1, CDKN1A; 116899) has
been mapped to 6p21.2. It is a short 21 kd protein, which inhibits
the activity of CDK2 activated by cyclins D1, E and A, therefore
inhibiting several phases of the cell cycle. Its expression is
regulated at transcriptional level by p53, thus making this CDKI
one of the effectors of DNA-damage induced cell cycle arrest at
the G1/S and G2/M checkpoints. The successful cell cycle arrest,
mediated by p21cip1 will protect cells against DNA damage-
induced apoptosis and conversely the inactivation of the protein
will favour the induction of the p53-dependent apoptosis.
Additionally the truncation of the C terminus of the protein by
caspases 3 (and possibly other caspases) in apoptotic cells leads
to a loss of the nuclear localisation signal, exit from the nucleus
and loss of cell cycle inhibitor activity. As an inhibitor of the G1/
S transition point it plays a part in the cell cycle exit and the
activation of the differentiation programme in many cell types.
The allelic variants of the gene are associated with elevated risk
of tumours (http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?
id=116899).
Another member of the family, p27kip1 (CDKN1B, 600778),
was mapped to 12p13. In quiescent cells relatively high levels of
the protein are expressed, but protein expression rapidly declines
upon cell cycle induction. The CDK inhibitory activity of the
protein is linked to its nuclear localisation, while the cytoplasmic
accumulation of the protein is associated with high proliferative
activity of certain cancers. The phosphorylation and ubiquitina-
tion of the protein leads to the segregation of p27kip1 in the
cytoplasm followed by its degradation. The truncation of p27kip1
by caspase 3 in apoptotic cells leads to the deactivation of this
CDKI similar to p21cip1. Germline variants of the gene have been
found associated with increased risk of certain cancers (http://
www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600778).
The third member of this CDKI protein family is p57kip2
mapped to 11p15.5 (CDKN1C; 600856). The CDK inhibitor
region of the protein is highly homologous with the p21cip1
protein. However, unlike the previous two members of the
family the p57kip2 is partially imprinted, the maternal allele
being preferentially expressed. Loss of function (mutations on
the gene, loss of maternal allele) was found to be associated with
sporadic cancers as well as hereditary syndromes such as
Simpson–Golabi–Behmel syndrome and Beckwith–Wiede-
mann syndrome (http://www.ncbi.nlm.nih.gov/entrez/dispo-
mim.cgi?id=600856).
All three proteins have been found to be expressed in the
cytoplasm of neurones in AD patients [29–32], often in tangle
bearing neurones and distorted neuritic processes of plaques.
The association with tangles and sequestration in the cytoplasm
imply inactive CDKIs, which would explain the cell cycle
regulatory failure at the G1/S transition point and uninhibited
progression of neurones through DNA replication. However,
the inconsistent expression pattern of the three proteins andlarge variations from one patient to another imply that AD is a
heterogeneous disorder associated with the deactivation of
different CDKIs in different patients. The question is, though
what inactivates the CDKIs in neurones? Truncation by
caspases in apoptotic cells is a tempting possibility. However,
neurones appear to avoid the classical apoptotic process exactly
due to the fact that they do not amplify their downstream
cascade of caspases, including caspases 3 [33].
In summary, it appears likely that the inactivation of CDKIs
plays a major role in the G1/S regulatory failure in neurones
responsible for the development of AD-type pathology.
However, the causes of this inactivation remain elusive.
3. The causes of the G1/S regulatory failure in AD
There is evidence in the literature suggesting that the cell
cycle regulatory failure in AD is not restricted to neurones. It
has been shown that there is an association between solid
tumours and the incidence of AD [34]. Additionally peripheral
cell, such as lymphocytes from AD patients showed altered
response to mitogenic stimulation relative to control subjects
[35,36]. Fibroblasts collected from AD patients also shown an
aberrant cell cycle-dependent Ca response [37]. A more recent
study has found that the differential phosphorylation of Erk1
and Erk2 in response to bradykinin in fibroblasts can distinguish
AD patients from healthy elderly and patients suffering from
non-AD dementias [38].
We have also found that this specific failure of the G1/S
transition checkpoint is not restricted to neurons alone.
Lymphocytes of AD sufferers also show signs of G1 regulatory
failure [39]. Additionally, in subjects showing neuropsycholo-
gical signs of pre-clinical AD, the lymphocyte response was
similar to that seen in AD patients [39].
These findings also imply that the AD-related G1/S
regulatory failure is probably due to genomic variations of the
cyclin dependent kinase inhibitors (CDKIs) involved in the
regulation of the G1/S transition.
In order to investigate this possibility we genotyped a
relatively small but unselected group of AD patients and control
subject (which included both healthy elderly people and patients
suffering from other non-AD dementias). We have concentrated
on known, mainly cancer-related SNPs on the p21cip1 p27kip1
and p57kip2 genes.
There are two variants on the p21cip1 gene associated with
increased tumour frequency [40–42]. One of the variants is a
Ser-to-Arg substitution in codon 31 while the other was a C-to-T
change in the 3-prime untranslated region of the p21cip1 gene
20 bp following the stop codon. The amino acid substitution is
within the CDKI region of the protein, and probably affects the
binding of the inhibitor to the cyclin CDK complex. The role of
the intronic SNP is less clear, but it has been suggested that it
might affect the stability of the mRNA and alter protein levels in
the cytoplasm.
We have genotyped the patients using the methods described
previously [40]. No homozygous patient occurred in our cohort.
The simultaneous presence of both variants increased the risk of
developing AD slightly, albeit significantly (Table 1). Inte-
Table 1






Relative frequency % Odds ratio
AD 21 184 10 1.64
Men 10 84 11 1.97
Women 11 100 10 1.42
Control 20 288 6
Men 8 133 6
Women 12 155 7
Odds ratio calculations indicate an association between the variant and
Alzheimer's disease. This association is stronger in men.
Fig. 2. The number of cyclin B positive neurones has been assessed using a
semiquantitative scale (0, occasional=0.1, some=0.5, many=1). The average
number of cyclin B positive neurones (y axis) is significantly larger in
patients with the variant p21cip1. Error bars represent the standard error of the
means.
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dependent (Table 1), similar to IGF-1R [43] ABCA1 [44] and
ESR2 [45].
We have also found that the presence of the two SNPs on
p21cip1 was associated with a reduced age of onset (p=0.002)
(Fig. 1) in AD patients (both males and females).
In late (neocortical) stage AD patients (n=59, of which 9 had
variant p21cip1) the number of Cyclin B positive (G2 phase)
neurones was significantly higher in patients with the p21cip1
variant (Fig. 2), indicating that the variant is associated with the
progression of the cell cycle in neurones. In early stage
(entorhinal) patients (n=40, of which 5 had variant p21cip1)
however, the p21cip1 variant was associated with significantly
lower levels of synaptophysin (Fig. 3).
The p21cip1 protein is also responsible for the cell cycle arrest
in response to oxidative stress induced DNA damage down-
stream of p38. Thus the functional loss of p21cip1 may lead to
deficiencies in the neuronal stress-response. In this context it is
interesting that earlier studies found that both mitogenic
stimulation and oxidative stress are required for the progression
of AD [27].
For p27kip1 we analysed the effect of the Gly-to-Val
polymorphism on codon 109. The VV genotype has been
found to be associated with increased risk of cancer [46]. The
polymorphism lies in the p38jab1 binding domain of the protein
and probably reduces the CDKI activity of the protein by
altering its degradation. We found that the VV genotype also
increases the risk of AD (Odds Ratio 1.72, p=0.049) (Table 2).
However, this SNP had no effect on the age of onset of dementia
in our AD patients (data not shown).Fig. 1. The age of onset in Alzheimer's patients is reduced in the presence of the
variant p21cip1 gene. y axis indicates the age of onset in years, error bars indicate
the standard error of the means. All 205 AD patients (see Table 1) were included
in the analysis.There are no SNPs on the p57kip2 gene known to be
associated with cancer and the known SNPs are not char-
acterised in terms of population diversity. We have found that
the SNP on codon 159, which leads to an Ala-to-Val
substitution, is associated with an increased risk (Odds
Ratio=1.66, no statistical significance due to small sample) of
AD in a small group of patients (Table 3). The presence of the
SNP was also associated with a significantly (p=0.04) reduced
age of onset in our AD patients (Fig. 4). The polymorphism
does not lie within the CDKI domain of p57kip2. The function of
the region affected is not known. The interpretation of these, in
terms of their functional significance, is made more complex by
the fact that p57kip2 is imprinted.
4. New early diagnostic possibilities for Alzheimer's
disease
The discovery of the pathogenic pathway responsible for the
development of Alzheimer's disease holds the promise of early
diagnostic protocols, novel biomarkers and disease-modifying
therapies for Alzheimer's disease.
As mentioned earlier, there are two types of biomarkers.
The antecedent biomarkers measure the exposure to
environmental risk and genetic risk factors, allowing a more
accurate risk prediction for an individual patient.
In this sense all the factors which contribute to the mitogenic
stimulation of mature neurones can be regarded as antecedent
biomarkers. Elevated plasma homocysteine levels, low thyroid
and oestrogen levels can all be included in this category.Fig. 3. Synaptophysin expression in the Ca1 region of the hippocampus.
Synaptophysin levels were measured using radioimmuhistochemistry and image
analysis. The amount of synaptophysin is expressed as nCi/g tissue (y axis).
Error bars represent the standard error of the means.
Table 2
The relative frequency of the variant p27kip1 gene in AD patients and age
matched control subjects
Diagnosis AA109 G/G AA109 V/G AA109 V/V
AD 3 (4.05%) 34 (45.94%) 37 (50%)
Control 9 (11.39%) 41 (51.89%) 29 (39.18%)
Patient numbers and the relative frequency values (expressed in %).
Fig. 4. The age of onset in Alzheimer's patients is reduced in the presence of the
p57kip2 variant. The y axis indicates the age of onset in years, error bars indicate
the standard error of the means. All AD patients with the relevant genotypes (see
Table 3) were included in the analysis.
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development the genetic polymorphisms on the CDKI genes
described above also constitute antecedent biomarkers. How-
ever, since neither the potential mitogenic stimuli nor the G1/S
regulatory failure lead to AD-type changes in neurones on their
own, the real risk of developing AD is only present in
individuals where both types of risk factors are present. In this
context risk assessment in any individual patient would require
multiple tests, including genotyping for several genes, and the
determination of complex risk-profiles.
The disease biomarkers indicate the presence of phenomena
or factors which are either a pre-clinical or a surrogate
manifestation of the disease. These markers allow early
diagnosis of individual patients but they are also important for
the stratification of clinical trials.
Recent studies suggest that the identification of disease
biomarkers, based on detecting the AD-type cell cycle
deregulation, is possible.
The proliferative capacity and survival of cultured lympho-
cytes is altered in AD patients relative to age-matched controls
[35,47]. The apparent discrepancy between the two reports may
have several reasons. Besides the possible differences in the
selection/inclusion criteria for AD patients and controls, the
experimental design and measures of lymphocyte proliferative
capacity in the two studies were different. It is also known that
the proliferative potential of peripheral lymphocytes is affected
by age, therefore even slight differences in the age of AD
patients and controls will affect the outcome of these studies. In
addition, in an individual patient, the use of COX-2 inhibitor
NSAIDS, or a simple cold might alter the response of the
lymphocytes to mitogenic stimulation in vitro. Larger con-
trolled studies would be required to clarify the cause of the
apparent discrepancy.
The specific G1/S regulatory failure, typical to neurones in
AD, is also detectable from lymphocytes [39]. The study was
aimed specifically at the detection of any defects of the G1/S
transition control. We found that in response to cell cycle
inhibitors the relative lengthening of the G1 phase in expo-
nentially proliferating peripheral lymphocytes was significantly
reduced in AD patients even when the clinical picture was
atypical due to other co-existing disease processes. The test alsoTable 3
The relative frequency of the variant p57kip2 gene in AD patients and age
matched control subjects
Diagnosis AA159 A/A AA159 A/V AA159 V/V
AD 29 (53.70%) 21 (38.89%) 4 (7.41%)
Control 73 (65.77%) 31 (27.93%) 7 (6.31%)
Patient numbers and the relative frequency values (expressed in %).identified the early, pre-clinical stage AD patients. It is
reassuring that the results of patients suffering from non-AD
dementias were similar to the control group. The effect of the cell
cycle inhibitor rapamicin used to induce G1/S arrest depends on
the integrity and expression of the p27kip1 CDKI. The presence
of the polymorphism on p27kip1 described earlier could explain
the lack of response to rapamicin. The other finding of the study
was that in lymphocytes from AD patients sub-lethal oxidative
stress did not induce cell cycle arrest to allow for DNA-repair.
This finding was later replicated in fibroblasts from AD patients
[48]. At least in a subset of patients this phenomenon might be
due to the p21cip1 polymorphism associated with increased risk
of AD and an earlier onset. Since oxidative stress is one of the
factors believed to be necessary for the development of AD [27],
the lack of the repair mechanisms could certainly explain the
earlier appearance of the pathology.
The recent finding of differential Erk1 and Erk2 phosphor-
ylation in response to bradykinin [49,50] (inflammatory agonist
and G1 inhibitor) in fibroblasts from AD patients [38] further
strengthens the hypothesis that that p27kip1 mediated cell cycle
responses are aberrant in AD patients and could be used as an
early diagnostic marker for the disease.
The early peripheral markers of the G1/S regulatory failure
appear to perform well as disease biomarkers and would be
equally useful in clinical practice and drug trial design.
However, more controlled studies are necessary to validate
and standardise the protocols designed to identify patients with
AD-type cell cycle regulatory deficits. The main caveat of
course of these markers is that, although they identify AD
patients accurately and early, they do not reflect the progression
of the disease and cannot be used as outcome measures in
clinical trials.
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